Rapt Therapeutics (NASDAQ:RAPT) Receives “Hold” Rating from TD Cowen

TD Cowen restated their hold rating on shares of Rapt Therapeutics (NASDAQ:RAPT) in a research report sent to investors on Tuesday morning,Benzinga reports.

Several other equities analysts also recently commented on the company. Piper Sandler downgraded Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price target on the stock. in a report on Tuesday. Cowen downgraded Rapt Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Company set a $72.00 price objective on Rapt Therapeutics and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Leerink Partners raised Rapt Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $16.00 to $37.00 in a report on Friday, September 26th. Finally, Barclays dropped their price objective on shares of Rapt Therapeutics from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Rapt Therapeutics presently has a consensus rating of “Hold” and an average target price of $48.22.

Rapt Therapeutics Trading Up 64.0%

Rapt Therapeutics stock opened at $57.57 on Tuesday. Rapt Therapeutics has a 1-year low of $5.67 and a 1-year high of $57.61. The firm’s fifty day simple moving average is $33.31 and its 200-day simple moving average is $23.72. The company has a market capitalization of $1.60 billion, a P/E ratio of -5.21 and a beta of 0.45.

Rapt Therapeutics (NASDAQ:RAPT) last posted its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.23. On average, equities research analysts predict that Rapt Therapeutics will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Rapt Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RAPT. Bridgeway Capital Management LLC increased its stake in shares of Rapt Therapeutics by 32.0% during the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock worth $532,000 after purchasing an additional 5,000 shares during the period. Dimensional Fund Advisors LP bought a new stake in Rapt Therapeutics in the 3rd quarter valued at $231,000. Millennium Management LLC grew its holdings in Rapt Therapeutics by 75.2% in the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company’s stock valued at $1,013,000 after buying an additional 16,854 shares in the last quarter. UBS Group AG increased its position in Rapt Therapeutics by 680.3% during the 3rd quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after buying an additional 25,116 shares during the period. Finally, Susquehanna International Group LLP increased its position in Rapt Therapeutics by 173.4% during the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company’s stock worth $1,170,000 after buying an additional 28,782 shares during the period. Institutional investors own 99.09% of the company’s stock.

Key Headlines Impacting Rapt Therapeutics

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to acquire Rapt in a definitive deal valuing the company at about $2.2 billion (~$58.00 per share), providing a cash exit at a sizable premium to recent trading and directly causing the stock’s sharp rise. Article Title
• Positive Sentiment: Multiple outlets highlight that GSK gains a late‑stage food allergy antibody (ozureprubart) from Rapt’s pipeline — a strategic fit that supports the acquisition rationale and the deal premium. Article Title
• Positive Sentiment: Rapt’s investors and prior backers benefit: Forbion confirms this is a successful exit from its Growth Fund III, which validates the deal’s value to venture/early investors. Article Title
• Neutral Sentiment: Analysts have mostly left ratings and price targets around the announced deal price (Wells Fargo equal weight with $58 PT; Lifesci/TD Cowen hold), which implies limited near‑term upside beyond the acquisition consideration. Article Title
• Negative Sentiment: Several law firms have announced investigations or shareholder class‑action interest probing whether Rapt’s board negotiated a fair price, which could lead to litigation, procedural delays or settlement costs ahead of closing. Investors should monitor any formal complaints. Article Title
• Neutral Sentiment: Coverage pieces and buy/analysis notes (e.g., Seeking Alpha, The Motley Fool) frame Rapt as an attractive biotech target highlighting its long‑acting IgE candidate; useful context for strategic rationale but secondary to the binding deal terms. Article Title

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.